Profile of Xeomin^® (incobotulinumtoxinA) for the treatment of blepharospasm

References

• Daniele RanouxCGPractical Handbook on Botulinum ToxinMarseilleSolal Editeurs2007
   Google Scholar
• DresslerDComplete secondary botulinum toxin therapy failure in blepharospasmJ Neurol20002471080981011127541
   PubMed Web of Science ®Google Scholar
• FruehBRFeltDPWojnoTHMuschDCTreatment of blepharospasm with botulinum toxin. A preliminary reportArch Ophthalmol198410210146414686385932
   PubMedGoogle Scholar
• ScottABKennedyRAStubbsHABotulinum A toxin injection as a treatment for blepharospasmArch Ophthalmol198510333473503977705
   PubMedGoogle Scholar
• JankovicJClinical efficacy and tolerability of Xeomin® in the treatment of blepharospasmEur J Neurol200916Suppl 2141820002742
   PubMed Web of Science ®Google Scholar
• JostWHBlümelJGrafeSBotulinum neurotoxin type A free of complexing proteins (XEOMIN®) in focal dystoniaDrugs200767566968317385940
   PubMed Web of Science ®Google Scholar
• HarrisonARChemodenervation for facial dystonias and wrinklesCurr Opin Ophthalmol200314524124514502050
   PubMedGoogle Scholar
• DresslerDBotulinum toxin for treatment of dystoniaEur J Neurol201017Suppl 1889620590814
   PubMed Web of Science ®Google Scholar
• BrinMFBlitzerABotulinum toxin: dangerous terminology errorsJ R Soc Med19938684934948078064
   PubMed Web of Science ®Google Scholar
• AlbaneseATerminology for preparations of botulinum neurotoxins: what a difference a name makesJAMA20113051899021205970
   PubMed Web of Science ®Google Scholar
• FrevertJXeomin® is free from complexing proteinsToxicon200954569770119292989
   PubMed Web of Science ®Google Scholar
• GreenePFahnSDiamondBDevelopment of resistance to botulinum toxin type A in patients with torticollisMov Disord1994922132178196686
   PubMed Web of Science ®Google Scholar
• RoggenkamperPJostWHBihariKComesGGrafeSEfficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasmJ Neural Transm2006113330331215959841
   PubMed Web of Science ®Google Scholar
• BeneckeRJostWHKanovskyPRuzickaEComesGGrafeSA new botulinum toxin type A free of complexing proteins for treatment of cervical dystoniaNeurology200564111949195115955951
   PubMed Web of Science ®Google Scholar
• BeneckeRCurrent status of the use of Botulinum neurotoxin type AEur J Neurol200916Suppl 2120002738
   PubMed Web of Science ®Google Scholar
• HasegawaKWatanabeTSuzukiTA novel subunit structure of Clostridium botulinum serotype D toxin complex with three extended armsJ Biol Chem200728234247772478317581814
   PubMed Web of Science ®Google Scholar
• DresslerDManderGJFlinkKEquivalent potency of Xeomin® and Botox®Mov Disord200823Suppl 1S20S21
   Web of Science ®Google Scholar
• HambletonPClostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical useJ Neurol1992239116201311751
   PubMed Web of Science ®Google Scholar
• FrevertJDresslerDComplexing proteins in botulinum toxin type A drugs: a help or a hindrance?Biologics2010432533221209727
   PubMedGoogle Scholar
• OhishiISugiiSSakaguchiGOral toxicities of Clostridium botulinum toxins in response to molecular sizeInfect Immun1977161107109326664
   PubMed Web of Science ®Google Scholar
• ChenFKuziemkoGMStevensRCBiophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex speciesInfect Immun1998666242024259596697
   PubMed Web of Science ®Google Scholar
• FujinagaYTransport of bacterial toxins into target cells: pathways followed by cholera toxin and botulinum progenitor toxinJ Biochem2006140215516016954533
   PubMed Web of Science ®Google Scholar
• JinYTakegaharaYSugawaraYMatsumuraTFujinagaYDisruption of the epithelial barrier by botulinum haemagglutinin (HA) proteins – differences in cell tropism and the mechanism of action between HA proteins of types A or B, and HA proteins of type CMicrobiology2009155Pt 1354519118344
   PubMed Web of Science ®Google Scholar
• JohnsonEABradshawMClostridium botulinum and its neurotoxins: a metabolic and cellular perspectiveToxicon200139111703172211595633
   PubMed Web of Science ®Google Scholar
• BlümelJNT 201 – a new botulinum neurotoxin A. A preparation free of complexing proteins demonstrating the safety and benefit of decreased total clostidial protein burdenJ Parkinsonism Relat Disord200511Suppl 2S267
   Google Scholar
• AokiKRRanouxDWisselJUsing translational medicine to understand clinical differences between botulinum toxin formulationsEur J Neurol200613Suppl 4101917112345
   PubMed Web of Science ®Google Scholar
• De AlmeidaATDe BoulleKDiffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applicationsJ Cosmet Laser Ther20079Suppl 1172217885882
   PubMedGoogle Scholar
• PickettADoddSRzanyBConfusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applicationsJ Cosmet Laser Ther200810318118318608706
   PubMed Web of Science ®Google Scholar
• DoddSLRowellBAVrabasISArrowsmithRJWeatherillPJA comparison of the spread of three formulations of botulinum neurotoxin A as determined by effects on muscle functionEur J Neurol19985218118610210830
   PubMed Web of Science ®Google Scholar
• Tang-LiuDDAokiKRDollyJOIntramuscular injection of 125I-botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: time course of tissue distributionToxicon200342546146914529727
   PubMed Web of Science ®Google Scholar
• JankovicJKenneyCGrafeSGoertelmeyerRComesGRelationship between various clinical outcome assessments in patients with blepharospasmMov Disord200924340741319053054
   PubMed Web of Science ®Google Scholar
• JankovicJComellaCHanschmannAGrafeSEfficacy and safety of NT 201 (Botulinum neurotoxin free from complexing proteins) in blepharospasmNeurology200972Suppl 3 Abstr 346.
   Google Scholar
• FridayDBigalkeHFrevertJIn vitro stability of botulinum toxin complex at physiological pH and temparatureNaunyn Schmideberg’s Arch Pharmacol2002365Suppl 2 Abstr 46.
   Google Scholar
• BrinMFDosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Spasticity Study GroupMuscle Nerve Suppl19976S208S2209826992
   PubMedGoogle Scholar
• GreinSManderGJTaylorHVXeomin® is stable without refrigeration: Complexing proteins are not required for stability of botulinum toxin type A preparationsToxicon20085113 Abstr 36.
   Web of Science ®Google Scholar
• FrevertJXeomin: an innovative new botulinum toxin type AEur J Neurol200916Suppl 2111320002741
   PubMed Web of Science ®Google Scholar
• LeeJCYokotaKArimitsuHProduction of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutininMicrobiology2005151Pt 113739374716272395
   PubMed Web of Science ®Google Scholar
• AtassiMZOn the enhancement of anti-neurotoxin antibody production by subcomponents HA1 and HA3b of Clostridium botulinum type B 16S toxin-haemagglutininMicrobiology2006152Pt 718911895 discussion1895189716804163
   PubMed Web of Science ®Google Scholar
• JankovicJVuongKDAhsanJComparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystoniaNeurology20036071186118812682332
   PubMed Web of Science ®Google Scholar
• NaumannMAlbaneseAHeinenFMolenaersGReljaMSafety and efficacy of botulinum toxin type A following long-term useEur J Neurol200613Suppl 4354017112348
   PubMed Web of Science ®Google Scholar
• EiseleKTaylorHVBlümelJImmunogenicity of NT201 (Xeomin®) in Cynomolgus monkeys following high-dose injectionsMov Disord200823Suppl 1S15
   Google Scholar
• BlümelJFrevertJSchwaierAComparative antigenicity of three preparations on botulinum neurotoxin A in the rabbitNeurotox Res20069238
   Google Scholar
• KanovskyPPlatzTComesGGrafeSSassinINT 201, botulinum neurotoxin free from complexing proteins (Xeomin®) provided sustained efficacy and was safe in spasticity: 89 weeks long-term dataJ Neurol Sci2009285Suppl 1S75S76
   Web of Science ®Google Scholar
• Xeomin®: Summary of product characteristicsGreensboro, NCMerz Pharmaceuticals2010
   Google Scholar
• DresslerDBeneckeRPharmacology of therapeutic botulinum toxin preparationsDisabil Rehabil200729231761176818033601
   PubMed Web of Science ®Google Scholar
• DresslerDClinical features of antibody-induced complete secondary failure of botulinum toxin therapyEur Neurol2002481262912138306
   PubMed Web of Science ®Google Scholar
• BorodicGJohnsonEGoodnoughMSchantzEBotulinum toxin therapy, immunologic resistance, and problems with available materialsNeurology199646126298559392
   PubMed Web of Science ®Google Scholar
• OdergrenTHjaltasonHKaakkolaSA double blind, randomised, parallel group study to investigate the dose equivalence of Dysport® and Botox® in the treatment of cervical dystoniaJ Neurol Neurosurg Psychiatry19986416129436720
   PubMed Web of Science ®Google Scholar
• RanouxDGuryCFondaraiJMasJLZuberMRespective potencies of Botox® and Dysport®: a double blind, randomised, crossover study in cervical dystoniaJ Neurol Neurosurg Psychiatry200272445946211909903
   PubMed Web of Science ®Google Scholar
• DresslerDRoutine use of Xeomin® in patients previously treated with Botox®: long term resultsEur J Neurol200916Suppl 22520002739
   PubMed Web of Science ®Google Scholar
• DresslerDManderGJFlinkKEquivalent potency of Xeomin® and Botox®Toxicon200851Suppl 11018045635
   PubMed Web of Science ®Google Scholar
• Xeomin® (incobotulinumA) injection [prescribing information]Greensboro, NCMerz Pharmaceuticals, LLC2010
   Google Scholar
• Botox®: Summary of product characteristicsIrvine, CAAllergan Inc2010
   Google Scholar
• Dysport®: Summary of product characteristicsSlough, UKIpsen Ltd2009
   Google Scholar